Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival
- 31 December 2009
- journal article
- Published by Elsevier BV in Clinical Immunology
- Vol. 133 (3), 333-352
- https://doi.org/10.1016/j.clim.2009.08.007
Abstract
No abstract availableKeywords
This publication has 86 references indexed in Scilit:
- How regulatory T cells workNature Reviews Immunology, 2008
- Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1New England Journal of Medicine, 2008
- Adoptive cell transfer: a clinical path to effective cancer immunotherapyNature Reviews Cancer, 2008
- Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancerGynecologic Oncology, 2007
- Principles of adoptive T cell cancer therapyJCI Insight, 2007
- Tregs and rethinking cancer immunotherapyJCI Insight, 2007
- A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian CancerClinical Cancer Research, 2006
- Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patientsCancer Immunology, Immunotherapy, 2006
- Role of IFN-g in induction of Foxp3 and conversion of CD4+CD25- T cells to CD4+ TregsJCI Insight, 2006
- Regulatory T cells, tumour immunity and immunotherapyNature Reviews Immunology, 2006